Understanding MASH: An Examination of Progression and Clinical Outcomes by Disease Severity in the TARGET-NASH Database
Progression to all-cause mortality in patients with MASH was significantly associated with the presence of higher fibrosis stage and cirrhosis. Cardiometabolic comorbidities such as T2D and hypertension were prevalent in patients with MASH progression. Early identification and management of MASH may mitigate disease progression and liver-related complications.
Authors
- Rakesh Luthra
- Aakash Sheth (ORCID: https://orcid.org/0000-0003-3041-5525)
Institutions
- Novo Nordisk (United States) (US)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2024-12-30
- DOI
- https://doi.org/10.1007/s12325-024-03085-4
- Citations
- 6
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.32